Contact
Eduardo Sabaté
[Link]/in/sabate A Strategic-minded, Pragmatic Cross-Functional Medical Lead.
(LinkedIn) Basking Ridge, New Jersey, United States
Top Skills Summary
Cross-functional Team Leadership
A STRATEGIC-MINDED, PRAGMATIC CROSS-FUNCTIONAL
Market Access
MEDICAL LEAD. TRAINED ON EVIDENCE GENERATION TO
Drug Development
SATISFY ALL STAKEHOLDERS’ NEEDS (HCPs, PAYERS,
Languages REGULATORS, AND PATIENTS). EXPERIENCED GLOBAL
STRATEGIST/LAUNCH-READINESS TEAM LEADER.
English (Native or Bilingual)
Spanish (Native or Bilingual)
French (Limited Working)
Italian (Limited Working)
Experience
Portugues (Limited Working)
Gilead Sciences
Senior Director, Medical Affairs - Oncology
July 2021 - Present (2 years 11 months)
United States
Global Medical Affairs – Magrolimab Heme/Solid tumours: Lead the
magrolimab expanded access programs (Won 2023 Gilead’s Medical
Innovation Tournament Award). Designed and implemented two Expanded
Access Programs in the US and a Named-Patient Compassionate Use in
Europe; Evidence Generation: Scientific lead for ISR/Collaborations. Lead the
development of the Integrated (cross-functional) Evidence Generation Plan
for magrolimab. Responsible for providing Medical input to non-interventional
studies, such as HEOR, Patient Engagement and RWE projects; Global
Development Teams: Represent GMA Magrolimab in the Hematology, Solid
Tumour and Pediatric GDTs. Previous role in Medical Affairs Research –
Heme/Solid Tumours: Led a team responsible for the development and
execution of MA Research Plans of Action (POA) for Magrolimab. Scientifically
demonstrated the value of Gilead’s medicines by identifying their place in
therapy, optimizing treatment practice, and improving patient outcomes using
retrospective database analyses, prospective cohort studies, PROs, and RWE;
Created/co-developed study concept documents, protocols, analysis plans,
final study reports, and manuscripts. Contributed to assessing data gaps and
provide input on clinical and PRO endpoints with Phase II/III/IV clinical trials
in partnership with Medical Affairs, Clinical Development, and Commercial;
Developed scientific communications (e.g., manuscripts, scientific forum
presentations, slide decks) to build the peer-reviewed published scientific
Page 1 of 8
evidence base; Maintained and continued to enhance knowledge of technical
and methodological advances and trends to ensure the best approaches are
used in studies and evaluations; Engaged key clinical and methodological
experts on various research projects. Provided methodological support at
advisory boards, educational programs, conferences, and other external
meetings. Co-authored ten abstracts and one manuscript.
Daiichi Sankyo, Inc.
Sr Dir RWE - Global Medical Affairs Oncology
October 2019 - May 2021 (1 year 8 months)
Basking Ridge, NJ
Designed processes and templates to streamline the development of RWE
strategies into the Medical Affairs Plans. Supported Global Medical Teams
(GMAT) in the development of Evidence Generation Strategies and Plans.
Provided scientific advice in the design of RWE studies for HCPs and
Patients (RWE defined any study that is not a conventional RCT for regulatory
purposes). Piloted the process by co-creating several cross-functional, cross-
regional RWE sub-teams (under GMAT). Provided quality review of projects
and publications for several products/tumor types: Enhertu (BC HER2+, CRC,
and GC), Pexidartinib, Valemetostat. Since Sept 2020, I am also working on
Enhertu (BC HER2-low, LC), 1402 LC, and 1062 (LC). Co-led the DS Global
RWE Expert Team.
AbbVie
Dir. Solid tumours - GMAP
April 2018 - August 2019 (1 year 5 months)
Greater Chicago Area
Led the development of GMAP strategies for all solid tumours compounds in
Ph3 and Launch readiness stages (i.e. Depatux-M, Rova-T, Veliparib). As a
core member of the Asset Development Team, Global Evidence Team, and
Global Brand Team, I provided insights on payers’ evidence needs, and value-
based pricing strategy to inform strategic investment/development decisions.
Developed a new GMAP Strategic Plan template based on the 175 plan
format. Budget aprox. $1.5 MM/year.
Merck Group
Senior Director, Oncology Pipeline and BD - GMAP
November 2016 - March 2018 (1 year 5 months)
Geneva Area, Switzerland
Page 2 of 8
A member of Global Market Access and Pricing (GMAP) leadership team. Led
the development of early market access and pricing strategies for all pipeline
and in-licensing oncology compounds.
Roche Glycart AG
10 years 4 months
R&D Project Team Leader - Cancer Immunotherapies (Vize-Director)
July 2014 - October 2016 (2 years 4 months)
Zurich, Switzerland
Reporting to the head of Oncology research and Roche’s pRED Committee,
I was accountable for the design and execution of product development and
commercialization strategies. Successfully managed and motivated two cross-
functional teams (CEA-CD3 TCB and IDO/TDO programs). Successfully
presented/gained the support of the pRED governance committee for projects’
development strategies (including TPPs, CDP, commercial potential, EIP/
CLS endorsements, and other investment requests). Led two successful IND/
CTA and several Ph1/2 trial regulatory submissions in the US and several
EU countries. In collaboration with early commercial and medical leads,
defines/prioritize TPPs and potential label wording. In collaboration with the
clinical development lead, implemented innovative development pathways that
enabled the team to cut half the clinical development time of CEA-TCB (CLS
to EIH in 13 months; Mono to combo with aPD-L1 Tecentriq in 12 months).
Ensured a long-term vision and strict cross/functional coordination/planning
that enabled an accelerated progression of the projects (i.e. manufacture
at-risk investments). Introduced changes in team dynamics, by ensuring
transparent and informed decision/making at all sub-team levels, an efficient
escalation of issues/decisions, and rapid discussions/alignment/decisions
on critical issues. Introduced the planning in terms of strategic options and
alternative development paths, so as to be prepared for different potential
scenarios. Effectively communicated projects’ vision, plans, and risks.
Oversighted and coordinated the dissemination/communication of scientific/
clinical evidence to internal/external stakeholders. Accountable for the
resources approved for these projects (up to CHF20 million). Work reference
available upon request.
International Payer Strategy Leader - Avastin Gyn Franchise
January 2011 - June 2014 (3 years 6 months)
Basel Area, Switzerland
Led International Payer Strategy (affiliates) and Access & Value teams
(evidence generation), in the development of Global HEOR, Value Proposition,
Page 3 of 8
and Payer Evidence strategy for Avastin for the Gyn Franchise; Core member
of Lifecycle and Business teams. Ad-hoc in Medical and Development teams.
Led the generation of HEOR/RWE evidence, models, dossiers, tools and
publications supporting indications in the launch phase (from LIP to PhIV/
registries). Provided input on PRO, MRU, health economics into PhIII-IV trials;
organized value advisory boards and internal/external workshops. Managed
multiple agencies. Managed budget ~ CHF 1.2M.
• Led Avastin global HEOR/payer strategy, including the use of US claims
databases/retrospective chart reviews when needed, for 7 indications in
3 tumour types: BC (AVADO, Ribbon1, Ribbon2), OC (GOG218/ICON7,
OCEANS, AURELIA) and Cervix (GOG240);
• Co-authored 4+ international posters and articles, led development of 7 value
dossiers and strategic plans, 10+ epidemiological/CEA models, 12+ IPST
meetings, 4 advisory boards and 5+ global value summits;
• Led development of Roche’s Payer Marketing Framework and guided its
global implementation;
• Led the development of the “PFS as a Clinically Meaningful Endpoint” – a
strategic guidance to evidence.
Selected Accomplishments:
• Led Avastin global HEOR/payer strategy for 7 indications in 3 tumour types:
BC (AVADO, Ribbon1, Ribbon2), OC (GOG218/ICON7, OCEANS, AURELIA)
and Cervix (GOG240);
• Co-authored 4+ international posters and articles, led development of 7 value
dossiers and strategic plans, 10+ epidemiological/CEA models, 12+ IPST
meetings, 4 advisory boards and 5+ global value summits;
• Led development of Roche’s Payer Marketing Framework and guided its
global implementation;
• Led the development of the “PFS as a Clinically Meaningful Endpoint” – a
strategic guidance to evidence.
Medical Affairs Secondment
July 2013 - December 2013 (6 months)
As part of my professional development plan, I worked with the Medical Affairs,
Lifecycle and Int’l Medical teams in the development of the Avastin Cervical
Cancer 2014 Annual Medical Plan and disease background training material.
International Economics Strategy Leader (Prokurist)
July 2006 - December 2010 (4 years 6 months)
Basel Area, Switzerland
Led Clinical Outcomes and HE research strategy, dossiers, tools and
reimbursement dossiers strategy for Avastin CRC, GBM, LC and BC; Led the
Page 4 of 8
development of Evidence-Based Global Pricing and Reimbursement. Advised
affiliates on RWE/registry design to support capping program. Member of
Lifecycle and Business teams. Led International HEOR Strategy Team.
Managed multiple agencies and a budget ~ CHF 1.5M.
• Led Avastin global HEOR/P&R launch for 5 indications in 5 tumour types: BC
(E2100), LC (4599/AVAiL), RCC (AVOREN), CRC (966), and rGBM (BRAIN).
• Co-authored 7+ international posters, led development of 5 value dossiers
and plans, 5+ epid/CEA models, 7+ IPST meetings, and 5 global value
summits.
• Co-led the design and implementation of Avastin 2007 evidence-based
pricing strategy, which included pay-per-performance deals and the registries/
platforms needed to collect the clinical and cost data (i.e. RWE; Avastin global
capping program).
• Led Avastin global P&R launch for 5 indications in 5 tumour types: BC
(E2100), LC (4599/AVAiL), RCC (AVOREN), CRC (966), and rGBM (BRAIN).
• Co-authored 7+ international posters, led development of 5 value dossiers
and plans, 5+ epid/CEA models, 7+ IPST meetings, and 5 global value
summits.
• Co-led the design and implementation of 2007 pricing strategy which
included pay-per-performance arrangements for Avastin, including RWE data
collection (i.e. Avastin global capping program registries).
Merck Group
Corporate Health Economics Manager (Merck-Serono SA)
January 2005 - June 2006 (1 year 6 months)
Geneva Area, Switzerland
Led global clinical outcomes and HE strategy for all therapeutic areas including
CNS (RRMS – Rebif), inflammatory (psoriasis/RA – Raptiva), and HRT;
generated economic and policy evidence for product reimbursement and
advocacy. Supported local negotiations with payers.
• Developed clinical value strategy and models for Rebif and Raptiva
successfully supporting their price;
• Organized advisory boards and set up the MUSIQoL steering committee
(Development of a PRO tool);
• Developed white papers on health policy that supported the company’s
advocacy efforts.
• Developed value strategy and models for Rebif and Raptiva successfully
supporting their price;
• Organized advisory boards and set up the MUSIQoL steering committee;
Page 5 of 8
• Developed white papers on health policy that supported the company’s
advocacy efforts.
World Health Organization
Medical Officer
February 2000 - December 2004 (4 years 11 months)
Managed medical and scientific affairs for the assigned projects. Generated
evidence to support advocacy activities aiming to increase governments’
support to the provision of health care for chronic conditions; acted as focal
point for pharmaceuticals in the department. Interacted with government
officers around the world, UN diplomats, technical officers within WHO and
other non-governmental and research organizations. Published reports
and articles in peer-reviewed journals. Supervised two interns. Selected
Accomplishments:
• Edited and co-authored a book on Adherence to Long-Term Therapies, in
close collaboration with 15 co-authors and 300 supporters from 33 countries.
• Co-authored 6 articles and posters, 2 reports, 3 report chapters and 4
symposia on Adherence to therapies in major international congresses
(chaired the scientific committee for 3 of them).
• Played a pivotal role for the inclusion of Adherence to therapies in the global
public health agenda.
• Co-authored chapters of WHO report on “Priority Medicines for Europe and
the World” and contributed to the 2011 “WHO report on Health Systems”.
Harvard T.H. Chan School of Public Health
Research Fellow - Epidemiology
1998 - 2000 (2 years)
Greater Boston Area
Conducted research on burden of disease and cost-effectiveness analyses,
and their use in defining national health priorities and essential packages of
care. Performed retrospective data analyses of survey (i.e. NHANES), real-
world data (i.e. Framingham study for CVD modelling) and health plans claim
datasets. Performed systematic reviews and meta-analyses. Trained public
health officers worldwide, including CDC, MoH officers, and public health
professionals. As part of the Burden of Disease Unit (BDU) research team ,
contributed to achieve common research, publication, and training goals;
Selected Accomplishments:
• Collaborated in publication of several worldwide reports on health systems
and burden of disease methods with WHO;
Page 6 of 8
• Completed several projects with World Bank and Inter-American
Development Bank (see publications).
Wyeth
Market Research and Mkt Services Manager
1997 - 1997 (less than a year)
Market Research Manager: Headed market research department. Designed
primary and secondary market research and supervised other marketing
services; coordinated development of brand plans, ensuring alignment with
budgets, sales forecasts, and market trends. Directly supervised two market
research analysts and one administrative assistant. Product Manager: Led
the development of marketing strategies and tools for hospital-based products
(oncology: Novantrone and Methotrexate and antibiotics: Tazopril and Pipril).
Organized promotional stands, advisory boards and satellite seminars at major
national medical congresses; assisted the marketing director in the evaluation
of new commercial opportunities. Led a special hospital promotional force (six
people).
Wyeth
Product Manager Hospital Products
1996 - 1996 (less than a year)
Led the development of marketing strategies, key clinical messages and
Q&A for for Lederle’s recently acquired hospital-based products (oncology:
Novantrone & Methotrexate and antibiotics: Tazopril & Pipril). Led the
development of promotional, communication and training materials. Led
a special hospital promotional/sales force of six people (three in Caracas
and one in each major region); organized stands and satellite seminars at
major national medical symposia and congresses; organized Advisory Board,
including KoLs slides rehersals; built and maintained relationship with KOLs,
as well as with medical associations, media services providers and hospital
purchase managers; assessed the comparative advantages of antibiotics
using cost-per-successfully treated patient as a CE indicator; assisted the
marketing director in the evaluation of new commercial opportunities.
Sabate Ingenieria Biomedica SA
General Manager (Co-Owner)
1991 - 1995 (4 years)
Founded and managed a medical software company. In partnership with
CDR, led the design of medical software for offices and small hospitals,
including automatic uptake of medical devices (i.e. endoscopy, PACs, digital
Page 7 of 8
Rx, laboratory devices). Marketed our star product "WinMedica", coded in
VisualBasic 3.0 and Access SQL. Designed and installed peer-to-peer and
LAN Novel 3.1. Organized company’s participation in IT/medical symposia and
congresses. Assessed the clinical and financial impact of the use of medical
technologies on daily medical practice (productivity). In charge of recruiting,
training and managing a team of six technicians/programmers.
Various
Medical Practitioner
1990 - 1995 (5 years)
1993–95 Private medical practice (general medicine). Centro Profesional de
Clínicas Caracas. Venezuela. Private general practitioner (adult and women
primary health care).
1992–93 Ministerio de Sanidad y Asistencia Social (Venezuela) Rural
Physician. Clinical practice in underserved urban areas. Provided adult,
women and children primary health care. Implemented community health
programs (i.e. vaccination).
1990–92 Ministerio de Sanidad y Asistencia Social (Venezuela) Epidemiology
Practitioner. Assisted the development and analysis of regional
epidemiological information. Coordinated after-hours vaccinations, and
malaria/TB drugs support centers in the sub-region Caracas. Participated in
the design, implementation, and evaluation of regional vaccination programs.
Education
Harvard University School of Public Health
MPH, Health Care Management and HTA · (1997 - 1998)
Universidad Central de Venezuela
MD, Medicine · (1985 - 1992)
Universität Basel
European Certificate in Pharmaceutical Medicine, Pharmaceutical
Medicine · (2011 - 2013)
Universidad Metropolitana (VE)
MBA, Business · (1993 - 1995)
Page 8 of 8